F007 Complex Medical Dermatology Cases: Pearls and Pitfalls
DESCRIPTION
Many patients present with challenging skin manifestations posing diagnostic and therapeutic dilemmas. Using a case-based approach featuring complex medical dermatoses (including eczema, lupus, dermatomyositis, pyoderma gangrenosum, hidradenitis suppurativa, and inpatient dermatology), this session will highlight clinical pearls in making the diagnosis and elaborating treatment regimens as well as pitfalls to avoid. Management strategies based on the latest data from the literature will be reviewed, in addition to useful novel diagnostic tests.
LEARNING OBJECTIVES
Recognize clues in clinical presentation that aid in formulating accurate differential diagnoses in select complex medical dermatoses
Apply "tricks of the trade" and clinical pearls when elaborating a management plan for treating select complex medical dermatoses
SCHEDULE
9:00 AM
Hidradenitis suppurativa
Alexandra P. Charrow, MD, FAAD
9:18 AM
Pediatric eczema
Lisa Shen, MD, FAAD
9:36 AM
Inpatient dermatology
Zachary Holcomb, MD, FAAD
9:54 AM
Dermatomyositis
Gabriela Andrea Cobos, MD, FAAD
10:12 AM
Pyoderma gangrenosum
Robert Micheletti, MD, FAAD
10:30 AM
Lupus
Christina Lam, MD, FAAD
10:48 AM
Q&A
DIRECTOR
Christina Lam, MD, FAAD
SPEAKERS
Alexandra P. Charrow, MD, FAAD
Gabriela Andrea Cobos, MD, FAAD
Tufts Medical Center
Zachary Holcomb, MD, FAAD
Robert Micheletti, MD, FAAD
Lisa Shen, MD, FAAD
Boston University / Boston Medical Center
HANDOUTS
DISCLOSURES
Alexandra P. Charrow, MD, FAAD
Avalo – Consultant (1099 relationship)(Fees); Dermatology Foundation – Investigator(Grants/Research Funding); Hidradenitis Suppurativa Foundation – Board of Directors(No Compensation Received), Investigator(Grants/Research Funding); Incyte Corporation – Advisory Board(Fees), Investigator(No Compensation Received); Insmed – Investigator(No Compensation Received); Insmed Incorporated – Investigator(No Compensation Received); Novartis Pharmaceuticals Corp. – Advisory Board(Fees); Q32 Bio Inc. – Consultant (1099 relationship)(No Compensation Received); Sonoma Biotherapeutics – Investigator(No Compensation Received); UCB Pharma – Advisory Board(Honoraria); Wedbush Securities – Consultant (1099 relationship)(Honoraria);
Gabriela Andrea Cobos, MD, FAAD
AbbVie – Speaker(Fees); Apogee Therapeutics – Consultant (1099 relationship)(Fees); Biogen – Investigator(Honoraria); Bristol Myers Squibb – Speaker/Faculty Education(Fees); Bristol-Myers Squibb – Advisory Board(Honoraria); Dermira/Lilly – Advisory Board(Honoraria), Speaker/Faculty Education(Fees); Incyte – Advisory Board(Honoraria); Janssen Pharmaceuticals, Inc – Advisory Board(Honoraria), Speaker(Fees); Octapharma – Consultant (1099 relationship)(Fees); Priovant Therapeutics – Advisory Board(Fees); Sanofi/Regeneron – Advisory Board(Honoraria), Speaker(Fees); UCB – Advisory Board(Honoraria);
Zachary Holcomb, MD, FAAD
AstraZeneca – Investigator(Grants/Research Funding);
Christina Lam, MD, FAAD
Biogen – Consultant (1099 relationship)(Fees), Investigator(Fees); Priovant Therapeutics – Advisory Board(Fees);
Robert Micheletti, MD, FAAD
Boehringer Ingelheim – Investigator(Grants/Research Funding); Cabaletta Bio – Investigator(Grants/Research Funding); InflaRx – Investigator(Grants/Research Funding); Insmed – Investigator(Grants/Research Funding); Vertex Pharmaceuticals, Inc. – Consultant(Fees);
Lisa Shen, MD, FAAD
No financial relationships exist with ineligible companies.